BeiGene, Ltd.
ANTI-OX40 ANTIBODIES AND METHODS OF USE
Last updated:
Abstract:
The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer. In particular, the anti-OX40 antibody of the present invention does not interfere with the binding of OX40-ligand to its receptor.
Status:
Application
Type:
Utility
Filling date:
22 May 2019
Issue date:
15 Jul 2021